Overview
KINTOR PHARMA-B (9939)
Kintor Pharmaceutical Limited, a clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology. Its...
- Open
- 1.420
- High
- 1.420
- Low
- 1.310
- Prev. Close
- 1.390
- Volume
- 747.00K
- Turnover
- 999.74K
- Avg Price
- 1.338
- Bid/Ask Ratio
- 74.03%
- Amplitude
- 7.91%
- 52wk High
- 4.700
- Volume Ratio
- 1.33
- Turnover Ratio
- 0.15%
- 52wk Low
- 1.210
- HK Mkt Cap
- 663.22M
- Market CapHKD
- 663.22M
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -0.445
- EPSDynamic
- -0.350
- EPSStatic
- --
- BVPS
- 0.25
- P/B
- 5.27
- HK Shares
- 498.66M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 498.66M
- Min lot size
- 500
- Currency
- HKD
KINTOR PHARMA-B Analyst Rating
View moreForecast & Rating
Oct 16, 2024- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 1
- Buy
- 0
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Jul, 3
Kintor Pharmaceutical opened low and rallied, closing up 3.5%. The morning session started at HKD 1.970 and trended upward, accelerating in the afternoon to hit an intraday high of HKD 2.100 before settling at HKD 2.060 on turnover of approximately HKD 2.47 million. The rally was primarily fueled by positive news flow: the company previously announced its GT20029 gel achieved the primary endpoint in a Phase II clinical trial for acne in China, a milestone viewed as a pipeline breakthrough; additionally, insider confidence was signaled by shareholder KT International Investment Limited's recent share purchases at HKD 1.93 and HKD 2.20. Financially, Q4 2025 revenue surged 458% YoY to HKD 14.84 million, but net loss widened 45.7% to HKD 64.96 million, with EPS of -HKD 0.1396 and a net margin of -437.6%. While the stock closed below its session high of HKD 2.100, the persistent loss expansion underscores the gap between pipeline optimism and near-term profitability.
